Future of Shanghai RAAS Blood Products
CATEGORIES
- Asset Performance
- Innovation assets and pipeline
- Disruption vulnerability
- Company headlines
- Company’s future prospects
DATA ACCESS
Shanghai RAAS, established in 1988, is a Chinese blood product company. The company has eleven products, registered in about twenty countries, including coagulation factors, human immunoglobulin, human albumin and others. As of 2017, the company is among the few domestic producers that can export blood products. Shanghai RASS has been following its quality policy of "Safety, Quality, and Efficacy". Although, over 30 million products’ vials have been used, yet there is not even a single adverse reaction or any virus contamination reported due to its product quality. The company was listed on the Small-Medium Sized Enterprises Board of ShenZhen stock exchange in 2008 and became the largest blood products company in China and Asia through acquisitions and mergers in 2014.
Financial Health
Asset Performance
Innovation assets and Pipeline
All company data collected from its 2015 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page.
DISRUPTION VULNERABILITY
Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:
*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.
*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.
*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.
*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.
*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.